The property developer has backed Chinese Academy of Medical Sciences spinout Juventas to help advance its clinical-stage oncology cell therapy candidates.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

GlaxoSmithKline's corporate venturing unit is now an independent firm with a $500m fund anchored by its former parent.

MPM Capital and Qiming Venture Partners USA have co-led a series A round for Umoja Biopharma, based on research at Purdue University and Seattle Children’s Research Institute.

Cigna Ventures contributed to a placement for the Express Scripts and Walgreens Boots Alliance-backed turnkey pharmacy service.

The property developer took part in a $68.4m round that will help Juventas advance its clinical-stage oncology cell therapy candidates.

UCL and Francis Crick-founded Achilles has secured $69.9m in its series C round.

Berkeley Catalyst Fund-backed gene therapy developer 4D Molecular Therapeutics withdrew its last attempt in July.

Pfizer Ventures and Chiesi Ventures-backed gene therapy developer 4D Molecular Therapeutics withdrew its last attempt in July.

Aier Eye Hospital was among the participants in a series B-plus round that took the cancer treatment and test developer's overall funding to more than $65m.